Compounds which inhibit leukocyte adhesion mediated by VLA-4
US6583139B1 · kind B1 · utility
29Cited by
27References
26Claims
0Family size
Inventors
Key dates
| Filing date | Oct 17, 2000 |
| Grant date | Jun 24, 2003 |
| Priority date | — |
| Expiry date | Oct 17, 2020 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K38/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Disclosed as compounds which bind VLA-4. Certain of these compounds also inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by VLA-4. Such compounds are useful in the treatment of inflammatory diseases in a mammalian patient, e.g., human, such as asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, tissue transplantation, tumor metastasis and myocardial ischemia. The compounds can also be administered for the treatment of inflammatory brain diseases such as multiple sclerosis.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.